A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
SINGAPORE, March 17, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in the United States. This marks a significant milestone for HistoIndex as the company enters clinical care for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). 'I am excited to see how our core expertise in clinical trial assessments is now transcending into the realm of precise and personalized patient care,' said Dr. Gideon Ho, Chief Executive Officer of HistoIndex.' With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis.'
MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left untreated, leads to fibrosis and, ultimately, cirrhosis. After decades of research and therapeutic development, the field reached a pivotal moment in 2024 with the approval of Rezdiffra® - the first drug for the treatment of MASH with moderate to advanced fibrosis[1,2*]. As treatment options expand, accurate fibrosis assessment becomes even more critical in guiding clinical decisions and optimizing patient outcomes. HistoIndex has been playing a key role in the development of MASH treatments and is now leading the way in this next phase of patient care with FibroSIGHT.
FibroSIGHT seamlessly integrates into routine clinical workflows, leveraging on HistoIndex's proprietary stain-free imaging technology to enhance the sensitivity of fibrillar collagens detection — key in evaluating fibrosis severity in liver biopsy samples (see Figure 1). By eliminating variability associated with traditional staining techniques, FibroSIGHT delivers reliable and precise fibrosis assessment for MASH patients.
Clinicians can now order FibroSIGHT for MASH patients, on whom liver biopsies were performed, whenever definitive and accurate assessments of fibrosis are needed[2,3]. This includes use at the time of diagnosis to determine treatment decisions, when non-invasive assessments of degree of fibrosis are either inconclusive or discordant. Additionally, FibroSIGHT can be ordered post treatment to evaluate patients' response, especially in cases where there are no apparent improvement.
'By providing more accurate and objective evaluation of fibrosis, FibroSIGHT will enable more personalized treatment strategies and better evaluations of effectiveness of treatment leading to overall better care for patients,' commented Dr Naim Alkhouri, MD, Chief Medical Officer of Arizona Liver Health. 'Where biopsy evaluation is needed for a MASH patient, I can see incorporating FibroSIGHT in the workup, and in doing so, benefiting the entire MASH clinical care community.'
FibroSIGHT testing is performed in HistoIndex's CAP/CLIA accredited laboratory in Irvine, California. With the launch of FibroSIGHT, HistoIndex reaffirms its long-standing commitment in advancing fibrosis assessment and personalized treatment for MASH. By bridging research with clinical care, FibroSIGHT empowers informed treatment decisions, driving better patient care in the evolving landscape of liver disease management.
About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of Metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by steatosis and inflammation, which can lead to fibrosis (scarring), cirrhosis, liver failure, and an increased risk of liver cancer. The presence of ballooned hepatocytes (enlarged and damaged liver cells) is a key feature distinguishing MASH from simple steatosis. Pathologist assessments of liver biopsy remain the gold standard for diagnosing and assessing the severity of MASH. Histological categorial scoring systems are often used as surrogate endpoints to evaluate drug efficacy in clinical trials. These endpoints are limited in capturing the complex and heterogeneous nature of the disease. As a result, there is a growing need for more accurate and reliable tools, such as AI-based digital pathology solutions, to improve the assessment of treatment response and disease severity in MASH.
About HistoIndex
Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining cutting-edge biophotonic technology with AI-based analysis, HistoIndex provides innovative tools to improve the assessment of fibrosis changes and drug efficacy. HistoIndex's breakthrough digital pathology solutions are currently used in accelerating clinical research, expediting pharmaceutical drug development, and transforming medical standards.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
As Pilgrims Arrive in Makkah, Saudi Arabia Rolls Out Massive Operation to Safeguard Health
Massive health operation for world's largest religious gathering with 111,400 health services already delivered. 111,400 medical services delivered in first days Tens of thousands of health workers deployed 60% hospital bed capacity increase since 2024 MAKKAH, Saudi Arabia, June 5, 2025 /PRNewswire/ -- Saudi Arabia has deployed over 50,000 health workers and introduced advanced technologies to protect the health of pilgrims performing Hajj, the annual Islamic pilgrimage that represents one of the world's largest mass gatherings. The Ministry of Health reports 111,400 medical services have been delivered in the first days of the pilgrimage. New technologies include drones that deliver medical supplies in just 5 minutes, AI-augmented diagnostics and wearables to monitor vulnerable pilgrims. "I'm incredibly proud of our healthcare workers who are delivering comprehensive care around the clock. Their dedication has already provided 111,400 medical services since Hajj began and this level of support will continue for anybody that needs it," said His Excellency Fahad bin Abdulrahman AlJalajel, Saudi Minister of Health. Health infrastructure includes 183 medical facilities, 900 ambulances, and 11 air ambulance helicopters. The operation also includes the Middle East's first WHO-certified Special Medical Disaster Assistance Team on stand-by. Innovations and upgrades also include ambulance elevators installed at the Jamarat Bridge to transport patients directly to rooftop helipads for evacuation. Saudi Arabia has doubled the number of helicopter landing pads, with six now ensuring rapid evacuation of critical cases across the holy sites. The Seha Virtual Hospital, the world's largest, connects 224 facilities for remote consultations, new PET-CT scanners provide advanced diagnostics, while robotic surgeries have been launched this year for the first time at King Abdullah Medical City. Medical teams have performed 232 major surgeries including 18 open-heart operations to date. To mitigate extreme heat, the Kingdom has planted thousands of trees, installed hundreds of cooling stations and operates the world's largest air conditioning system in the Grand Mosque. The Ministry works with volunteers to distribute umbrellas while promoting multilingual guidance on crowd management, umbrella use, and hydration. The Ministry noted early signs that these joint efforts and adherence to crowd management plans have contributed to limiting the number of heat exhaustion cases this year, but that it would continue monitoring cases. The Ministry of Health commended the Royal Commission for Makkah, Ministry of Hajj and security personnel for their coordinated efforts in expanding shaded areas and crowd management to ensure safety and comfort. The technological innovations deployed with cross-government coordination during Hajj demonstrates how future health solutions can transform public health management at scale. The unprecedented operation comes as the five-day pilgrimage reaches its peak today on the Day of Arafah as pilgrims gather on Mount Arafat. Photo: View original content: Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
ISG to Evaluate Medical Device Service, Solution Providers
Upcoming ISG Provider Lens™ reports will cover providers helping companies integrate new technologies to make devices more capable, compliant and interoperable STAMFORD, Conn., June 05, 2025--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study evaluating digital transformation service and solution providers supporting the medical devices industry, exploring how they help device makers address technology challenges while accelerating innovation and time to market. The study results will be published in two comprehensive ISG Provider Lens™ reports, titled Medical Device Digital Services, covering the U.S. and European markets, respectively, and scheduled to be released in November 2025. The study will examine providers offering medical device companies end-to-end digital engineering and product development services; strategic consulting, quality assurance and regulatory compliance services; and digital solutions for post-market activities. In particular, it will assess provider ability to address technology challenges such as data interoperability and cybersecurity. Enterprise buyers will be able to use information from the reports to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. The medical device industry is embracing digital transformation by integrating AI, IoT and cloud technologies. These advancements enhance real-time monitoring and predictive diagnostics, facilitate improved clinical decisions and transform traditional hardware-centric models into dynamic, data-driven ecosystems. "Medical devices are quickly evolving to meet the new requirements of patient-centric healthcare," said Iain Fisher, director, ISG Provider Lens Research. "Device makers need to collaborate with providers on innovation and improve outcomes to remain competitive in the market." ISG has distributed surveys to more than 100 providers of medical device services and solutions. Working in collaboration with ISG's global advisors, the research team will produce three quadrants representing the digital services and solutions most commonly used by medical device companies, based on ISG's experience working with its clients. The three quadrants are: Digital Engineering and Product Development, evaluating providers with expertise in designing and enhancing interconnected, software-driven, compliant medical devices. Providers are assessed on their abilities to apply emerging technologies such as AI, ML, digital twins and edge computing to accelerate innovation, ensure compliance and reduce time to market. Regulatory Compliance, Strategy and Quality Assurance, assessing providers that help medical device manufacturers navigate global regulatory frameworks and align engineering initiatives with go-to-market objectives. Providers implement cybersecurity and data protection strategies, ensuring product and patient safety in connected and software-driven environments. Post-Market Digital Enablement, covering providers that deliver digital solutions for continuous monitoring, device tracking and telehealth integration. Providers focus on developing and integrating remote patient monitoring systems, analytics and post-market surveillance tools. Geographically focused reports from the study will cover digital services and solutions offered to medical device companies in the U.S. and Europe. ISG analysts Rohan Sinha (U.S.) and Sneha Jayanth (Europe) will serve as authors of the reports. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as digital transformation solution and service providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens™ evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged to complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens™ Research The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Julianna Sheridan, Matter Communications for ISG+1 978-518-4520isg@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
